Development of Diheteroamide-based Small Molecules as a Novel Class of HIV-1 Inhibitors with Improved Safety Profile

Peter K. Cheung 1, Maryam Zamiri 2, P. Richard Harrigan 1,3, Alan Cochrane 4, David S. Grierson 2

1.  BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada. 2. Faculty of Pharmaceutical Sciences, UBC, Vancouver, BC, Canada. 3. Department of Medicine, UBC, Vancouver, BC, Canada 4. Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada

Background

Initial screens of compounds capable of inhibiting HIV-1 gene expression identified a stilbene-based compound 5350150 (Ref. 1) which significantly reduced the production of HIV-1 Gag and Env. However, the known photolabile/toxic properties of stilbene compounds rendered the molecule unsuitable for long-term treatment options. Here we report the identification of GPS 488, a nonphotolabile/nontoxic analogue of 5350150 where the C=C double bond has been replaced by an amide isostere, that GPS 488 markedly reduced associated cytotoxicity, and displayed anti-HIV activity against a comprehensive panel of multidrug-resistant strains.

Methods

An exploratory library of fifty 5350150-amide analogues was prepared using the acyl fluoride–TMS amine condensation protocol. The evaluation of the antiretroviral activity of this collection was determined by a T-cell reporter assay that expresses green fluorescent protein upon HIV infection. The level of infection was monitored using flow cytometric analysis (guavaSoft 2.2™ software, Guava HT8, Millipore™). The antiviral activity of compound GPS 488 was evaluated in the assay that measures inhibition of HIV-1 spread in a co-culture of CEM-GXR cells containing one percent of HIV-1 infected cells. Infection was performed in a 96-well plate containing serial dilutions of molecule GPS 488, and the half-maximal effective concentration (EC50) values were determined on day 3 post infection. To investigate the potential adverse effect on cell viability, we employed Guava ViaCount™ assay (Millipore) on the same reporter cells. In brief, CEM-GXR cells were seeded in 96-well plates 80,000 cells/well in the absence or presence of compound GPS 488 in concentrations ranging between 1.25 M and 100 M. Twenty-four hours later, 25 μL of cell suspension was mixed with 225 μL of Guava ViaCount™ reagent, and the mixture was incubated for 5 min at room temperature. Sample acquisition and data analysis were performed with the selection of EasyFit analysis feature using the ViaCount™ software module.

Results

Anti-HIV-1 activity was found to varying degrees for the 5350150 amide analogues, and one of the most potent compounds GPS488, was studied in detail. Compound GPS488 exhibited activity against wild-type HIV-1NL4.3 (subtype-B), and HIV-1 97USSNS54 (subtype-A) with EC50 values of 1.3 μM and 1.0 μM, respectively. For multidrug-resistant viruses, GPS488 inhibited an HIV-1 variant resistant to both NRTI and NNRTI with EC50 of 1.2 μM. Compound GPS488 was also active against viruses resistant to protease inhibitors, integrase inhibitors, and CCR5 antagonist inhibitors with EC50’s of 1.2 μM, 1.0 μM, and 1.0 μM, respectively. The potential cytotoxicity of GPS488 was measured by Guava ViaCount Assay. At the range of concentrations tested, a decrease in cell viability from 98.9% at 1.25 μM to 59.2% at 100 μM was observed.

Table 1. Mutations in HIV-1 proteins associated with resistance to ARVs

<table>
<thead>
<tr>
<th>Drug resistant HIV-1 Strain</th>
<th>Viral protein</th>
<th>Primary Mutations</th>
<th>EC50 for GPS 488</th>
<th>Resistance to ARV’S</th>
</tr>
</thead>
<tbody>
<tr>
<td>E00443</td>
<td>Reverse - Transcriptase</td>
<td>K103N, D67N, K70R, Y115F, Q151M, M184V, K219Q</td>
<td>1.2 μM</td>
<td>EFV, NVP, 3TC, ABC, AZT, and FTC</td>
</tr>
<tr>
<td>2948</td>
<td>Protease</td>
<td>G48V, 1.0 μM</td>
<td>1.2 μM</td>
<td>ATV and LPV</td>
</tr>
<tr>
<td>11845</td>
<td>Integrase</td>
<td>G140S, Q148H</td>
<td>1.0 μM</td>
<td>RAL, EVG, and DTG</td>
</tr>
<tr>
<td>MVC-res</td>
<td>Envelope-V3</td>
<td>A197, L208, T22A, E252D, I26V</td>
<td>1.0 μM</td>
<td>MVC</td>
</tr>
</tbody>
</table>

Figure 1. Anti-HIV-1 activity of GPS 488 against wild-type subtype A and B, and drug-resistant viruses. A: Emtricitabine (FTC) against wild-type HIV-1NL4-3 (subtype B), and 97USSNS54 (subtype A) as a positive control. B: GPS 488 against wild-type subtype A and B. C: GPS 488 against (N)NRTI-resistant isolate, and PI-resistant isolate. D: GPS 488 against IN-resistant isolate, and maraviroc-resistant R5 strain.

Figure 2. Evaluation of anti-HIV-1Bal activity (column) and GXR-CEM cell viability (line) for 5350150 (A) and GPS 488 (B) at concentrations between 62.5 nM and 16 μM for 5350150, and between 10 nM and 10 μM for GPS 488. HIV-1 infection and viability in CEM-GXR cells was assessed by measuring GFP positive cells and cell count, respectively 3 days after infection. For viable cell counts, the gate in a flow cytometer was set to cover 95% of the freshly passaged uninfected CEM-GXR cell. Results were expressed from three independent experiments for both the anti-HIV-1 activity and cell viability assays.

Figure 3. Evaluation of GPS 488 on CEM-GXR cell viability in the Guava ViaCount assay. Cells were analyzed after 24 h incubation with GPS 488 in concentrations ranging between 1.25 μM and 100 μM. Results are expressed as the percentage (%) of viable cells ± SEM of three independent experiments.

Table 1. Mutations in HIV-1 proteins associated with resistance to ARVs

Conclusions

- Compound GPS 488 inhibits both HIV-1 subtype A, R5 tropic and subtype B, X4 tropic at the low micromolar range.
- Compound GPS 488 remains active against a panel of HIV-1 strains that are resistance to the current 4 major drug targets at the EC50 values between 1.0 μM and 1.2 μM.
- A decrease in cell viability from 98.9% to 59.2% was observed in the presence of 100 μM of GPS 488.
- In comparison with stilbene-based compound 5350150, compound GPS 488 markedly reduced associated cytotoxicity in CEM-GXR cells.


Conflict of Interest Disclosure: “I have no conflicts of interest.”